Through innovative LNP delivery platforms and deep collaboration, we overcome traditional barriers to enable safer, more targeted in vivo therapies for meaningful patient impact.
Non-viral delivery of nucleic acids faces persistent challenges, including liver toxicity, limited repeat dosing capability, application constraints, and reduced tissue specificity. Conventional lipid nanoparticle (LNP) systems further highlight these limitations, with liver-biased biodistribution, PEG-associated immunogenicity, and instability during nebulization. Together, these barriers constrain the therapeutic potential of mRNAs, gene editing tools, in vivo CAR constructs, and oligonucleotides.
LNPs exhibit natural liver specificity, thereby limiting delivery to extrahepatic tissues.
Accumulation of LNPs in the liver can lead to off-target effects and hepatotoxicity.
Anti-PEG antibodies cause accelerated blood clearance and limit repeat dosing.
Traditional LNPs tend to aggregate and lose EE%
during nebulization, reducing their effectiveness for
inhaled delivery.
Cytodigm’s novel LNP delivery platforms replace PEG-lipids with sialic acid (SA)-containing gangliosides, eliminating PEG-mediated immunogenicity and enabling extrahepatic targeting. This design supports delivery of diverse nucleic acid payloads across multiple tissues, including the liver, spleen, lung, and eye. Together, these capabilities enable new treatment strategies across autoimmune, pulmonary, ophthalmic, and oncologic diseases, among others.
